This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
Preliminary power calculations were performed. These suggested that an overall sample of 440 was required to give at least 90% power (alpha=0.05) to detect a difference between proportions of at least 15% in the primary health outcomes. Thus, the study aimed to randomise a sample of 500 patients to take into account losses to follow-up. Of the 821 patients invited to participate in the two study centres, 630 agreed to be included in the study. However, 130 were not enrolled for a variety of reasons, such as ineligibility, refusal and surgery date problems. Therefore, the study sample comprised 500 patients, of which 249 were in the ECCE group and 251 in the Phako group. However, 13 patients in the ECCE group and 5 in the Phako group did not receive the allotted treatment and a few patients in both groups switched to the other treatment. The final study sample included 232 patients in the ECCE group and 244 patients in the Phako group.
Study design
This was a randomised clinical trial, which was carried out in two centres (the Moorfields Eye Hospital in London and the Oxford Eye Hospital in Oxford). The unit of randomisation was the individual patient, with only one eye considered for cataract surgery. Randomisation was stratified by the surgeon with blocks of size four and six, and was performed using allocation codes in sealed, numbered, opaque envelopes. The patients were followed for one year and the outcomes were assessed at 3 and 6 weeks, 3 and 6 months, and one year after surgery. The loss to follow-up was 21 patients in the ECCE group and 22 patients in the Phako group. Spectacles were given at 3 weeks postoperatively in the Phako group and at 3 months in the ECCE group. The patient and the optometrists carrying out the follow-up assessment were blinded to the treatment assignment, but the optometrists could not be masked to the size and location of the surgical incision, which revealed the type of surgery.
Analysis of effectiveness
The basis of the analysis of the clinical study was intention to treat. Statistical regression analyses were conducted to adjust for possible confounding effects of prognostic factors such as age and gender. The primary health outcomes used in the effectiveness study were: the proportion of patients who achieved visual acuity of 6/9 (<0.2 logMAR) or better with and without spectacles; the combined outcome of visual acuity (6/9 or better) and refraction (within plus or minus 1 dioptre of the planned refraction); capsule rupture and/or vitreous loss as a complication during surgery; and the incidence of capsule opacity during the first year after surgery.
Minor complications and several secondary outcomes were also evaluated. At baseline, prognostic factors were balanced in the two study groups, which were then comparable.
Effectiveness results
Without spectacles, the proportions of patients who achieved good visual acuity in the ECCE and Phako groups were 11% and 33% at 3 weeks, (p<0.001), 15% and 36% at 6 weeks, (p<0.001), 19% and 35% at 3 months, (p<0.001), 21% and 38% at 6 months, (p<0.001), and 20% and 39% at 12 months, (p<0.001). With spectacles, the corresponding values were 68% and 87% at 3 weeks, (p<0.001), 78% and 90% at 6 weeks, (p=0.001), 80% and 93% at 3 months, (p<0.001), 86% and 92% at 6 months, (p=0.046), and 86% and 91% at 12 months.
The combined outcome of good visual acuity and refraction in the ECCE and Phako groups was reached in 51% and 67% of the patients at 3 weeks, (p<0.001), 57% and 69% at 6 weeks, (p=0.007), 60% and 69% at 3 months, (p=0.050), 65% and 67% at 6 months, (p=0.553), and 65% and 69% at 12 months, (p=0.361).
The incidence of capsule opacity during the first year after surgery was 29% in the ECCE group and 20% in the Phako group, (p=0.014).
